2017
DOI: 10.1016/j.ijpharm.2017.07.056
|View full text |Cite
|
Sign up to set email alerts
|

Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
53
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 57 publications
(53 citation statements)
references
References 135 publications
0
53
0
Order By: Relevance
“…TMZ preferentially induces autophagic death in GBM cells rather than apoptosis through PI3K/AKT/mTOR signalling pathway . However, further study demonstrates that persistent inhibition of PI3K/AKT/mTOR by TMZ can only induce autophagy transiently and promote drug resistance of GBM . In the meantime, combination with autophagy inhibitors or regulators can interfere with the therapeutic effects of TMZ for GBM .…”
Section: Introductionmentioning
confidence: 92%
“…TMZ preferentially induces autophagic death in GBM cells rather than apoptosis through PI3K/AKT/mTOR signalling pathway . However, further study demonstrates that persistent inhibition of PI3K/AKT/mTOR by TMZ can only induce autophagy transiently and promote drug resistance of GBM . In the meantime, combination with autophagy inhibitors or regulators can interfere with the therapeutic effects of TMZ for GBM .…”
Section: Introductionmentioning
confidence: 92%
“…Malignant glioma is an invasive intracranial tumor that grows rapidly and has extremely high recurrence (1,20). At present, postoperative chemotherapy has become a powerful strategy for the treatment of adult glioma patients (1,2,20). However, treatment has been particularly inefficient for glioma patients administered chemotherapeutic agents due to the existence of the BTB.…”
Section: Discussionmentioning
confidence: 99%
“…Glioma is characterized as a malignant brain tumor with a high recurrence rate, and surgery is utilized to remove the tumor (1,2). However, patients with glioma have a high mortality rate and an extremely poor prognosis (2).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Despite multidisciplinary treatment approaches, including surgical resection and radiotherapy, GBM has a low prognosis with an average survival period of 15 -18 months (124)(125)(126). A major challenge in the treatment of GBM is delivering the therapeutic drug across the blood-brain barrier (BBB), a network of specialized brain endothelial cells with intercapillary distances of ~40µm that tightly regulate ionic composition, prevent macromolecules and unwanted cells from entering the brain to protect the central nervous system (CNS) from neurotoxins (127)(128)(129)(130)(131). The use of targeted drug delivery with relatively small magnetic particles (<40-nm) has been suggested as an efficient way to cross BBB, target cancerous cells, and permit an ondemand release of anti-tumor drugs.…”
Section: Introductionmentioning
confidence: 99%